Clinical Trial Search

Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)

Primary: Event-free Survival — 29 percentage of participants

Primary: Immune Response — 7 Particpants

Primary: Maximum Tolerated Dose (MTD) — 20 mg LBH589

Primary: The Number of Confirmed Hematologic Responses (Complete, Partial, or Very Good Partial Response) — 39; 11; 9; 10 participants

Primary: Number of Patients Able to Collect >=6 x 106 CD34+ Cells/kg in <= 2 Collections. — 11; 0; 14 Participants — p=0.90

Primary: Number of Participants Achieving a Complete Response — 51 Participants

Primary: Intervention Attendance (Feasibility) — 50 percentage of participants

Primary: Overall Response Rate (ORR) — 2; 2; 12; 42 Participants

Primary: Count of Participants With Positive and Negative 18F-FDG PET CT and F18-NaF PET CT Imaging Results in Individuals With MGUS, SMM, and MM. — 0; 1; 5; 10 Participants

Primary: CR and Near CR Rates — 39; 22 percentage of participants

Primary: Number of Participants Who Achieved a Confirmed Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) During Treatment — 28; 16 participants

Primary: Percentage of Participants With 1-year Response Rate of CR/sCR — 52.9; 50.0 percentage of participants — p=0.3657

Primary: Fraction of Patients (n=3) for Whom a sdAb Could be Generated That Binds to the Idiotype of the Paraprotein. — 2 Participants

Primary: To Determine the Progression-free Survival of Patients With Multiple Myeloma Treated With Tandem Cycles of High-dose Melphalan Followed by High-dose Melphalan in…

Primary: Number of Participants That Had Any Grade ≤2, and 3, 4 and 5 Adverse Events Following Administration of T Cells Expressing Anti- Signaling Lymphocytic Activation…

Primary: Number of Participants With Pulmonary Toxicity — 32 Participants

Primary: Overall Survival — 68 Months

Primary: Maximum Tolerated Dose (MTD) — 1600 cGy

Primary: Number of Multiple Myeloma (MM) Participants Categorized by Clinical Characteristics — 342; 366; 48; 36 Participants

Primary: Phase I: Number of Patients With Dose Limiting Toxicity — 0; 0; 0; 0 Participants

Primary: 6B Antibody Response to Prevnar Vaccine in Peripheral Blood — 3.69; 7.58 fold change

Primary: Determination of Maximum Tolerated Dose and / or Recommended Dose and Dosing Regimen of MOR03087 — 16; 16; 16; 16 mg/kg

Primary: Percentage of Patients With an Objective Response — 31 percentage of patients

Primary: Best Response Prior to Tandem Autologous Stem Cell Transplant — 1; 4; 62; 1 Participants

Primary: Patients With Overall Confirmed Response — 3; 5; 10 participants

Primary: Progression-free Survival (PFS) Rate at 12 Months — 79 percentage of participants

Primary: The Number of Confirmed Responses (Complete Response [CR], Very Good Partial Response [VGPR], or Partial Response [PR]) — 0 participants

Primary: Percentage of Participants That Are Relapse-free 5 Years After Initial Therapy — 28 percentage of participants

Primary: Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants